The compound is being re-evaluated

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly(=65 years) Healthy Volunteers

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly (=65 years) Healthy Volunteers

Inclusion Criteria:

• Pre-anaesthesia assessment judged without remarks by the investigator.
• ASA physical status category 1 to 2 (up to and including 3 depending on applicable patient category)

Exclusion Criteria:

• Lack of a normal range of enzyme activity for BuChE
• Known or suspected history of hypersensitivity to drugs with a similar chemical structure or class to AZD3043 (e.g., emulsion-based products like Diprivan,Intralipid), allergies to soybean or peanut products or any other drugs intended for use during th
• Prolonged QTcF >450 ms or shortened QTcF <350 ms or family history of long QT syndrome.